Inhibrx Biosciences (INBX) Liabilities and Shareholders Equity (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Liabilities and Shareholders Equity data on file, last reported at $146.5 million in Q4 2025.

• Liabilities and Shareholders Equity for Q4 2025 came in at $146.5 million, down 18.97% year-over-year; the trailing twelve-month figure through Dec 2025 was $778.7 million (up 17.67% YoY), and the FY2025 annual result was $146.5 million, down 18.97% from the prior year.
• Liabilities and Shareholders Equity declined to $146.5 million in Q4 2025 per INBX's latest filing, from $177.5 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $307.9 million in Q4 2023 and troughed at $146.5 million in Q4 2025.
• A 3-year average of $218.5 million and a median of $217.3 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity plunged 41.29% in 2024, then retreated 17.92% in 2025.
• A 3-year view of Liabilities and Shareholders Equity shows it stood at $307.9 million in 2023, then slumped by 41.29% to $180.8 million in 2024, then fell by 18.97% to $146.5 million in 2025.
• Business Quant data shows INBX's Liabilities and Shareholders Equity at $146.5 million in Q4 2025, $177.5 million in Q3 2025, and $212.1 million in Q2 2025.